To mark Melanoma and Skin Cancer Awareness Month, dive into our curated collection of high-impact articles from Elsevier's Oncology Journal Network ➡️ spkl.io/601242CyO #melsm

Year of the Zebra: In Review! Amplifying voices in the rare disease community taught us the power of unity, awareness, & advocacy. Together, we've highlighted crucial issues & fostered a stronger support network. Let's keep pushing for progress & hope. spkl.io/601844Mis

Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing CRS + HIPEC

European Society of Surgical Oncology (ESSO) BASO~The Association for Cancer Surgery Andreas Brandl Delia Cortés Guiral Alvaro Arjona Faraz Khan

Prediction model➡️bit.ly/3K1bQGr
Article➡️bit.ly/3QNUMHP

Another study published in Clinical Lymphoma, Myeloma, & Leukemia (Oncology Advance) found that women with #multiplemyeloma were more likely to have high-risk cytogenetics.

#NationalWomensHealthWeek

📖 buff.ly/4dFtPQy

SPECIAL ISSUE - NUTRITION AND SARCOPENIA IN SURGICAL ONCOLOGY

Malnutrition in cancer patients: Causes, consequences and treatment options

European Society of Surgical Oncology (ESSO) BASO~The Association for Cancer Surgery STITCHES - the General Surgery Newsletter OncoAlert Oncology Advance Isacco Montroni Andreas Karakatsanis (he/him) riccardoaudisio

🔓OPEN ACCESS 🔓
👉bit.ly/3QV7gxF

Which data should be collected in adjuvant colon cancer trials❓💿

✅Consensus project from the IDEA and ACCENT international consortia👇

👉doi.org/10.1016/j.ejca…

EORTC Oncology Advance ESMO - Eur. Oncology Colorectal Cancer Alliance
#cancer #colorectal #oncology #MedX

The Lancet Annals of Oncology ☢️This means patients can often avoid radiotherapy, with its associated costs and side-effects.

Instead, they can be regularly monitored, with radiotherapy only used if their cancer shows early signs of coming back.

Find more on RADICALS-RT👇 10/10
bit.ly/3QGTjD1

Good to see RADICALS-HD in print. THanks to numerous colleagues and collaborators over 20 years authors.elsevier.com/sd/article/S01…

Results from the FIH study of first-in-class CDK4-selective inhibitor PF-07220060 with ET in HR+ HER2-MBC after prior CDK4/6i,
✅G3 neutropenia rate=18.2% (no G4)
✅ORR=32%, CBR=64%
✅PFS=8.1mo
👉Promising data as CDK4/6i move to the adjuvant setting
#AnnOnc #ESMOBreast24

🚆 🚂 from Brussels 🇧🇪 to Berlin 🇩🇪 and #ESMOBreast24

A reminder of this Editorial for a sustainable society in ESMO Open from the ESMO - Eur. Oncology Climate Change Task Force 🌱 🌍

I look forward to meeting you there!

#ESMOAmbassadors traintoandfromESMO

esmoopen.com/article/S2059-…

Recent review in ESMO Open 👉Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low #breastcancer . Read the full text here: pubmed.ncbi.nlm.nih.gov/38613914/
G Curigliano MD PhD Paolo Tarantino Sara Tolaney Rebecca Dent

Presented by Rebecca Dent at #ESMOBreast24 w/ simultaneous publication in Annals of Oncology 1st results of Impassion132 showing no benefit of adding #atezoliyumab to 1st line CT in pts w/ advanced #TNBC relapsing <12months.
#AnnOnc #BreastCancer tinyurl.com/5n99udja

The pivotal randomized phase 3 CAPItelllo-291 study that showed an improvement in PFS with the addition of AKTi capivasertib to fulvestrant led to the regulatory approval of the combination in HR+/HER2- MBC with one or more PIK3CA/AKT1/PTEN alteration.
#AnnOnc #ESMOBreast24

📢 #RWD in borderline resectable pancreatic cancer
Emerging evidence in ESMO Real World Data and Digital Oncology: spkl.io/60154NoI1 ESMO - Eur. Oncology

🔍 Study findings
- Neoadjuvant FOLFIRINOX associated with improved survival versus upfront surgery.